Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 30 |
Antibody drug conjugate (ADC) | 7 |
Bispecific antibody | 7 |
Small interfering RNA | 6 |
AAV based gene therapy | 5 |
Target |
Mechanism CXCR4 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date08 Sep 2023 |
Target |
Mechanism C5 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date18 Aug 2023 |
Target- |
Mechanism Magnetic resonance imaging enhancers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date23 Dec 2022 |
Start Date29 Nov 2024 |
Sponsor / Collaborator |
Start Date29 Nov 2024 |
Sponsor / Collaborator |
Start Date14 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Alirocumab ( PCSK9 ) | Angina, Unstable More | Approved |
Pozelimab ( C5 ) | CHAPLE syndrome More | Approved |
Dupilumab ( IL-4Rα ) | Asthma More | Approved |
Aflibercept ( PGF x VEGF-A ) | Wet age-related macular degeneration More | Approved |
Atoltivimab/maftivimab/odesivimab-ebgn ( EBOV glycoprotein ) | Hemorrhagic Fever, Ebola More | Approved |